Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.7000
+0.0290 (4.32%)
Mar 26, 2026, 4:00 PM EDT - Market closed

Revenue by Segment

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023
Period Ending
Dec '24 Dec '23
Biotechnology (Startups)
1.50M583.23K
Biotechnology (Startups) Growth
157.63%-
Total
1.50M583.23K
Total Growth
157.63%-

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023
Period Ending
Dec '24 Dec '23
United States
1.50M583.23K
United States Growth
157.63%-
Total
1.50M583.23K
Total Growth
157.63%-
Source: S&P Global Market Intelligence.